搜索结果: 1-15 共查到“感染性疾病学 Hepatitis C”相关记录16条 . 查询时间(0.046 秒)
Prevalence of Hepatitis B Surface Antigen in Pregnant Women in Beheshti Hospital of Kashan, Isfahan
Prevalence Hepatitis B Virus Hepatitis B Surface Antigen Pregnant Women
2015/11/9
Background: The transmission of hepatitis B virus (HBV) is parenteral, sexual and prenatal. Prevention of vertical transmission of HBV is extremely important, because HBV infection in early life usual...
中华医学会感染病学会分会Roles of hepatitis B virus in nephropahty课件
Roles hepatitis B virus nephropahty
2012/2/24
中华医学会感染病学会分会Roles of hepatitis B virus in nephropahty课件。
EASL Clinical Practice Guidelines:Management of chronic hepatitis B
Hepatitis B virus EASL guidelines Treatment Interferon alpha Nucleoside/nucleotide analogues
2011/4/2
Our understanding of the natural history of hepatitis B
virus (HBV) infection and the potential for therapy of the
resultant disease has improved. Several new and effective
antiviral agents have be...
Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Dual Infection
Hepatitis B virus hepatitis C virus coinfection epidemiology hepatocellular carcinoma
2011/4/2
Approximately 350 million people are infected with HBV worldwide, and the World Health Organization (WHO) estimates that approximately 170 million people are infected with HCV. HBV and HCV infection a...
Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients
chronic hepatitis coinfection HBV HCV histology
2011/4/2
Background:
The aim of the present study was to compare the histological characteristics of livers between chronic hepatitis C (CHC) patients with and without hepatitis B virus (HBV) coinfection.
Me...
Hepatitis B virus and hepatitis C virus co-infection:additive players in chronic liver disease?
Hepatitis B virus Hepatitis V virus genotypes Hepatitis C virus Hepadnavirus Interferon
2011/4/2
Hepatitis B virus (HBV) and hepatitis C virus (HCV) share modes of transmission and their combined infection is a fairly frequent occurrence particularly in areas where the two viruses are endemic and...
Understanding the Pathogenesis and Management of Hepatitis B/HIV and Hepatitis B/Hepatitis C Virus and Hepatitis B/Hepatitis C Virus
B/Hepatitis C Virus Management
2011/4/2
Hepatitis B virus (HBV) pathogenesis is influenced by a variety of factors
including coinfection with other viruses, most notably HIV and hepatitis C
virus (HCV). Dual virus infection can modify the...
Clevudine myopathy in patients with chronic hepatitis B
Clevudine Hepatitis B Adverse effects Myopathy
2011/4/2
Clevudine (L-FMAU) is a thymidine L-nucleoside analogue that was recently introduced for the treatment of chronic
hepatitis B virus infection. Previous studies showed that clevudine has potent and su...
Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B
Clevudine Telbivudine Mitochondrial toxicity Pegylated interferon
2011/4/2
The development of clevudine as a treatment for hepatitis B was terminated recently because of case reports of myopathy.
In each case, the onset of symptoms occurred between 8 and 13 months after the...
Treatment of viral hepatitis in China: better clinical research and improved practice
viral hepatitis therapeutics China advance
2011/4/2
Hepatitis virus infection, especially chronic infection
with hepatitis B virus (HBV) and hepatitis C virus
(HCV), is a serious issue to global public health.
Although the prevalence of HBsAg in the...
Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients
Virological biochemical entecavir treatment
2011/4/2
Hepatitis B virus (HBV) infection has a high prevalence
in China. Entecavir has shown superior efficacy over
lamivudine in Chinese nucleoside-naive chronic hepatitis B
(CHB) patients over 48 weeks,...
Monotherapy versus combination therapy for the treatment of chronic hepatitis B
Monotherapy versus therapy the treatment of chronic hepatitis B
2011/4/2
Nucleos(t)ide analogues, active against hepatitis B polymerase, suppress viral replication and improve clinical outcome. However, the emergence of drug-resistant mutants can result in treatment failur...
Hepatitis B virus is estimated to have infected 350 million individuals globally, accounting for over 500 000 deaths each year.1 An effective and widely available vaccine provides protection from infe...
HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B
HBeAg seroconversion in the treatment of chronic hepatitis B
2011/4/1
During the natural history of chronic hepatitis
B virus (HBV) infection, the loss of serum hepatitis B e
antigen (HBeAg) and the development of anti-HBe antibodies
(HBeAg seroconversion) mark a tra...
Seroprevalence of Hepatitis C Virus in the Families of the Patients with Hepatitis C Infection in Shahre-Kord,Iran
Intrafamilial transmission Hepatitis C virus ELISA Immunoblotting
2015/9/21
Background: Chronic hepatitis C is a major health concern around the world. Although transmission of hepatitis C virus (HCV) infection through parenteral exposure is well documented, sexual transmissi...